All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What treatment options are there for patients with CLL who are resistant to both BTKi and BCL2i?

Apr 3, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in lymphoma/CLL

During the ESH Translational Research Conference, the Lymphoma Hub was pleased to speak with Lukas Frenzel, University Hospital of Cologne, Cologne, DE. We asked, What treatment options are there for patients with chronic lymphocytic leukemia (CLL) who are resistant to both BTK inhibitor (BTKi) and BCL2 inhibitor (BCL2i)?

What treatment options are there for patients with CLL who are resistant to both BTKi and BCL2i?

Frenzel begins by defining double-refractory CLL and a sequential treatment regimen, followed by a discussion on first-line and next-line therapeutic options, stressing the importance of understanding the mode of resistance and further clinical trials. Frenzel then highlights a need to target MCL1, despite toxicities shown in trials. Finally, Frenzel explores cellular therapies, such as CAR T-cell therapy or bispecific antibodies, as ways to overcome resistance.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you